182 related articles for article (PubMed ID: 16219350)
1. Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes.
Musto P; Falcone A; Sanpaolo G; Bodenizza C
Leuk Res; 2006 Apr; 30(4):385-8. PubMed ID: 16219350
[TBL] [Abstract][Full Text] [Related]
2. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
3. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide.
Kelaidi C; Park S; Brechignac S; Mannone L; Vey N; Dombret H; Aljassem L; Stamatoullas A; Adès L; Giraudier S; de Botton S; Raynaud S; Lepelley P; Picard F; Leroux G; Daniel MT; Bouscary D; Dreyfus F; Fenaux P;
Leuk Res; 2008 Jul; 32(7):1049-53. PubMed ID: 18191202
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes.
Ferrero D; Darbesio A; Giai V; Genuardi M; Dellacasa CM; Sorasio R; Bertini M; Boccadoro M
Br J Haematol; 2009 Feb; 144(3):342-9. PubMed ID: 19036104
[TBL] [Abstract][Full Text] [Related]
7. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study.
Stebler C; Tichelli A; Dazzi H; Gratwohl A; Nissen C; Speck B
Exp Hematol; 1990 Dec; 18(11):1204-8. PubMed ID: 2226680
[TBL] [Abstract][Full Text] [Related]
8. Cyclosporin A and thalidomide in patients with myelodysplastic syndromes: Results of a pilot study.
Xiao Z; Xu Z; Zhang Y; Qin T; Zhang H; Fang L
Leuk Res; 2011 Jan; 35(1):61-5. PubMed ID: 20591481
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
Kasper C; Zahner J; Sayer HG
J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
[TBL] [Abstract][Full Text] [Related]
10. Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes.
Balleari E; Clavio M; Arboscello E; Bellodi A; Bruzzone A; Del Corso L; Lucchetti MV; Miglino M; Passalia C; Pierri I; Ponassi I; Oneto C; Racchi O; Scudeletti M; Vignolo L; Zoppoli G; Gobbi M; Ghio R
Leuk Res; 2011 Nov; 35(11):1472-6. PubMed ID: 21794914
[TBL] [Abstract][Full Text] [Related]
11. [Preliminary results of erythropoietin treatment of anemia in myelodysplastic syndromes and chronic lymphocytic leukemia].
Gałeza-Obrepalska B; Dwilewicz-Trojaczek J; Paszkowska M; Kuratowska Z
Pol Tyg Lek; 1996 May; 51(19-22):285-8. PubMed ID: 9289712
[TBL] [Abstract][Full Text] [Related]
12. [A study of erythropoietin use for myelodysplastic syndrome].
Márquez Saavedra E; Artacho Criado S
Farm Hosp; 2004; 28(6):395-401. PubMed ID: 15628941
[TBL] [Abstract][Full Text] [Related]
13. Lymphocyte 5'-nucleotidase and aminopeptidase N activity in patients on maintenance hemodialysis treated with human recombinant erythropoietin and 1-alpha-D3.
Stefanovic V; Mitić-Zlatkovic M; Radivojevic J; Vlahovic P
Ren Fail; 2005; 27(3):283-8. PubMed ID: 15957544
[TBL] [Abstract][Full Text] [Related]
14. [Erythropoietin treatment of anemia associated with multiple myeloma (MM) and myelodysplastic syndrome (MDS)].
Qiao ZH
Zhonghua Zhong Liu Za Zhi; 1993 Mar; 15(2):122-4. PubMed ID: 8223121
[TBL] [Abstract][Full Text] [Related]
15. High-dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: a retrospective investigation on 133 patients treated in a single institution.
Azzarà A; Carulli G; Galimberti S; Baratè C; Fazzi R; Cervetti G; Petrini M
Am J Hematol; 2011 Sep; 86(9):762-7. PubMed ID: 21850658
[TBL] [Abstract][Full Text] [Related]
16. Response to recombinant erythropoietin alpha, without the adjunct of granulocyte-colony stimulating factor, is associated with a longer survival in patients with transfusion-dependent myelodysplastic syndromes.
Musto P; Villani O; Martorelli MC; Pietrantuono G; Guariglia R; Mansueto G; D'Auria F; Grieco V; Bianchino G; Sparano A; Zonno A; Lerose R; Sanpaolo G; Falcone A
Leuk Res; 2010 Aug; 34(8):981-5. PubMed ID: 19931907
[TBL] [Abstract][Full Text] [Related]
17. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
[TBL] [Abstract][Full Text] [Related]
18. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes.
Stasi R; Brunetti M; Bussa S; Conforti M; Di Giulio C; Crescenzi A; Terzoli E; Vecchione A; Pagano A
Clin Cancer Res; 1997 May; 3(5):733-9. PubMed ID: 9815743
[TBL] [Abstract][Full Text] [Related]
19. Use of human recombinant erythropoietin and prednisone for treatment of myelodysplastic syndrome with erythroid predominance in a dog.
Boone LI; Knauer KW; Rapp SW; Stewart JF; Modiano JF
J Am Vet Med Assoc; 1998 Oct; 213(7):999-1001. PubMed ID: 9776997
[TBL] [Abstract][Full Text] [Related]
20. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance.
Saudan P; Halabi G; Perneger T; Wasserfallen JB; Wauters JP; Martin PY;
J Nephrol; 2006; 19(1):91-6. PubMed ID: 16523432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
